MYELOMA MINUTE | Up To The Minute News | 1.14.2021 |
|
|
 |
Key Trends in Myeloma Care for 2021 |
The use of powerful new treatments early in the disease, and four-to-five-year remissions for standard risk patients are just two of the many 2021 trends in patient care Dr. Brian G.M. Durie highlights this week. “We are very close to having the best strategies overall,” he says, "with realistic hopes of very long survivals.” |
|
 |
COVID-19 Vaccination and Myeloma Patients |
Read this page for the IMF’s latest recommendations on receiving the COVID-19 vaccine if you have multiple myeloma (MM), smoldering multiple myeloma (SMM), or monoclonal gammopathy of undetermined significance (MGUS). |
|
 |
Register NOW for the Best of ASH 2020 Webinar |
Dr. Brian G.M. Durie discusses key takeaways from the 2020 American Society of Hematology (ASH) annual conference for patients, caregivers, and others. This webinar featuring an ASH summary takes place TODAY at 4:00 p.m. PT / 7:00 p.m. ET. |
|
 |
Newly Diagnosed Myeloma CNE: New Strategies for Multiple Myeloma Care |
This activity on newly diagnosed multiple myeloma will include an overview of the disease, as well as current treatment workup and testing recommendations for multiple myeloma. Through the case studies of June and Lisa, our faculty will explore transplant eligibility, induction, and maintenance therapy. Please remember to complete parts 2 and 3 to receive a total of 1.5 CNE credits (3 sessions at 0.5 CNE). Free downloadable tools and resources are provided after completing the post-test and activity evaluation survey. |
|
 |
And This Too Shall Pass… |
Once again, the IMF is hosting a raffle for a 10-day stay at the Villa Ono Oasis in historic Kailua-Kona, Hawaii. While many of us have been affected by COVID-19, we hope to remind you that this too shall pass. If you purchase the winning $50 raffle ticket, you could find yourself just minutes from the Hawaiian coastline. The winner will be announced on April 2, 2021. Note: Bookings will be in the future based on mutual availability with you and the property owner. |
|
 |
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series |
This Week’s Question:
When patients test as having borderline high-risk smoldering myeloma, should they receive treatment? |
|
|
|
|
We Thank Our Sponsors:
|
Amgen; Bristol-Myers Squibb; Genentech; GSK; Karyopharm Therapeutics; Oncopeptides, Inc.; Sanofi-Genzyme; and Takeda Oncology |
We also thank individuals like you for your continued support! |
|
Join the conversation at The International Myeloma Foundation |
Facebook: /Myeloma | Twitter @IMFMyeloma | Instagram @IMFmyeloma
www.myeloma.org |
This email was sent by: The International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607-3421 Connect with the IMF InfoLine 1-800-452-2873 |
We respect your privacy and your preferences for communications of this nature. Home • Unsubscribe • Privacy Policy |
View as web page |